<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="interaction" /><meta name="keywords" content="" /><title>Lipid-regulating Drugs: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../383/theme.css" /><link type="text/css" rel="stylesheet" href="204/style.css" /><link type="image/x-icon" rel="shortcut icon" href="../../favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="bnf_int590-lipid-regulating-drugs.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.8/jquery.min.js"></script><script type="text/javascript" src="../../383/scripts.js"></script><style type="text/css">
          .contentsbox { position: fixed; z-index:1001; }
          .contentsbox_wrap { overflow: hidden; width: 20px; height: 130px; position: absolute; left: 0; top: 0; }
        </style><!--[if IE 8]>
          <style type="text/css">
          #p1 {
          float: left;
          padding-bottom: 15em;
          }
          </style>
          <![endif]--><!--[if lte IE 8]>
          <style type="text/css">
          #start-search input {
          height: 28px;
          padding-top: 8px;
          }
          @media screen {
          #pV {
          display: block !important;
          }
          }
          </style>
          <![endif]--><!--[if IE 7]>
          <style type="text/css">
          #start-search input {
          position: absolute !important;
          left: 0;
          top: 0;
          }
          .as-shadow {
          margin-left: -4px !important;
          color: silver;
          }
          </style>
          <![endif]--><!--[if lte IE 7]>
          <style type="text/css">
          .menu {
          height: 1%;
          }
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }

          #account-info ul li a {
          width: 12em;
          }
          #opts ul li span {
          width: 12em;
          }
          div.as-select ul li ul li span {
          width: 40em;
          }
          div.menu ul li ul li {
          float: left !important;
          }
          #pQ fieldset, #qd, #input-box, #pub-list, #start-search, #end-search {
          display: inline;
          float: left;
          height: 100%;
          padding: 0;
          margin: 0;
          position: relative;
          }
          #hM a, #hM a img {
          border: none;
          display: inline-block;
          float: left;
          }
          #qd input {
          float: left;
          display: inline-block !important;
          }
          #start-search input {
          height: 28px;
          padding-top: 8px !important;
          }
          #end-search, #end-search input {
          height: 36px !important;
          }
          #hM, #content, #searchForm, #purple-menu {
          width: expression(document.body.clientWidth > 63 * parseInt(document.body.currentStyle.fontSize) ? '63em': 'auto');
          margin: 0 auto;
          }
          #pQ {
          z-index: 1;
          }
          </style>
          <![endif]--><!--[if lte IE 6]>
          <style type="text/css">
          body {
          height: 100%;
          }
          div.menu ul li a, div.menu ul li span {
          display: inline-block;
          }
          div.menu ul li ul li {
          clear: both;
          }
          div.as-select ul li span {
          height: 20px;
          padding-top: 16px;
          padding-left: 1em;
          padding-bottom: 0;
          padding-left: 1em;
          margin: 4px 0;
          border-right: 1px solid #888;
          background-image: url("images/dropdown_img.png");
          background-repeat: repeat-x;
          overflow-x: hidden;
          }
          div.as-select ul li ul li span {
          font: bold 10px Verdana !important;
          padding: 4px 1em !important;
          color: #2D2D2D;
          background: white;
          text-decoration: none !important;
          white-space: nowrap;
          border: none !important;
          float: left;
          }
          div.menu span.hover {
          background: #8F1F8D;
          color: white;
          }
          </style>
          <![endif]--></head><body><!--[if lte IE 6]>
          <script type="text/javascript">
          jQuery(document).ready(function($) {
          $('a.mclogo').html('<img src="images/mc_logo.gif" class="logo" />');
          });
          </script>
          <![endif]--><?highlighter off?><div id="hC"><div id="vH"><div id="pU"><a class="mclogo" href="http://www.medicinescomplete.com/about/"><img class="logo" src="../../images/mc_logo.png" alt="MedicinesComplete" /></a><div id="hM"><div id="vM" class="menu"><ul><li><a href="http://www.medicinescomplete.com/mc/index.htm">Home</a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm">Help</a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=bnf_int590-lipid-regulating-drugs.htm">Feedback</a></li><li id="account-info"><a href="http://www.medicinescomplete.com/mc/account.htm">BNF.org Free Access</a><ul><li><a href="http://www.medicinescomplete.com/mc/account.htm">My Account</a></li><li><a href="http://www.medicinescomplete.com/mc/subscribe.htm">Subscribe</a></li><li><a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li><a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul></li></ul></div><a id="pD" accesskey="s" rel="bookmark" href="bnf_int590-lipid-regulating-drugs.htm#pB" title="Skip Navigation">Skip Navigation</a></div></div><div id="pA"><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 13 Mar 2013 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="search-in">Publication</label><label for="q">Search for</label><div id="qd"><div id="start-search"><div class="as-select menu" id="pub-list"><ul><li><span>British National Formulary</span><ul></ul></li></ul></div><div id="input-box"><input type="text" id="q" name="q" accesskey="4" /></div></div><div id="end-search"><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div></div></div><div id="pH"><div id="pN"><div id="pT"><!--[if lte IE 7]>
             
            <![endif]--><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF March 2013</a> &gt; <a href="PHP8848-interactions.htm">Appendix 1 Interactions</a> &gt; <a href="PHP8852-list-of-drug-interactions.htm">List of drug interactions</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="bnf_int1032-levamisole.htm" title="Previous: Levamisole">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="bnf_int970-ezetimibe.htm" title="Next: Ezetimibe">Next page</a> ►</div></div></div></div><div id="content"><div id="p1"><div id="pB"><?highlighter on?><h1>Lipid-regulating Drugs</h1><?highlighter off?><?highlighter on?><div id="pC" class="jN"><p><strong>Lipid-regulating Drugs</strong> has no specific interaction information.</p><p><strong>Ezetimibe</strong> belongs to <strong>Lipid-regulating Drugs</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span>plasma concentration of both drugs may increase when </span><span>ezetimibe</span> <span>given with</span> <span>ciclosporin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td><p><span></span> <span>ezetimibe</span> <span>possibly enhances anticoagulant effect of</span> <span>coumarins</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int594-fibrates.htm">Fibrates</a></td><td><p><span>increased risk of cholelithiasis and gallbladder disease when </span><span>ezetimibe</span> <span>given with</span> <span>fibrates</span><span>—discontinue if suspected</span></p></td><td></td></tr></tbody></table><p><strong>Bile Acid Sequestrants </strong> belongs to <strong>Lipid-regulating Drugs</strong> but has no specific interaction information.</p><p><strong>Colesevelam</strong> belongs to <strong>Lipid-regulating Drugs</strong> and has the following interaction information:</p><div class="cG"><p><strong>Note:</strong> Other drugs should be taken at least 4 hours before or after colesevelam to reduce possible interference with absorption </p></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span></span> <span>colesevelam</span> <span>reduces absorption of</span> <span>ciclosporin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int638-ethinylestradiol.htm">Ethinylestradiol</a></td><td><p><span></span> <span>colesevelam</span> <span>reduces absorption of</span> <span>ethinylestradiol</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int270-glibenclamide.htm">Glibenclamide</a></td><td><p><span></span> <span>colesevelam</span> <span>reduces absorption of</span> <span>glibenclamide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int738-levothyroxine.htm">Levothyroxine</a></td><td><p><span></span> <span>colesevelam</span> <span>reduces absorption of</span> <span>levothyroxine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span></span> <span>colesevelam</span> <span>possibly reduces absorption of</span> <span>phenytoin</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Colestipol</strong> belongs to <strong>Lipid-regulating Drugs</strong> and has the following interaction information:</p><div class="cG"><p><strong>Note:</strong> Other drugs should be taken at least 1 hour before or 4–6 hours after colestipol to reduce possible interference with absorption </p></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int810-bile-acids.htm">Bile Acids</a></td><td><p><span></span> <span>colestipol</span> <span>possibly reduces absorption of</span> <span>bile acids</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int478-cardiac-glycosides.htm">Cardiac Glycosides</a></td><td><p><span></span> <span>colestipol</span> <span>possibly reduces absorption of</span> <span>cardiac glycosides</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int525-diuretics-thiazide-and-related.htm">Diuretics, Thiazide and related</a></td><td><p><span></span> <span>colestipol</span> <span>reduces absorption of</span> <span>thiazides and related diuretics</span> <span>(give at least 2 hours apart)</span></p></td><td></td></tr><tr><td><a href="bnf_int216-tetracycline.htm">Tetracycline</a></td><td><p><span></span> <span>colestipol</span> <span>possibly reduces absorption of</span> <span>tetracycline</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int935-thyroid-hormones.htm">Thyroid Hormones</a></td><td><p><span></span> <span>colestipol</span> <span>reduces absorption of</span> <span>thyroid hormones</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Colestyramine</strong> belongs to <strong>Lipid-regulating Drugs</strong> and has the following interaction information:</p><div class="cG"><p><strong>Note:</strong> Other drugs should be taken at least 1 hour before or 4–6 hours after colestyramine to reduce possible interference with absorption</p></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1-acarbose.htm">Acarbose</a></td><td><p><span></span> <span>colestyramine</span> <span>possibly enhances hypoglycaemic effect of</span> <span>acarbose</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int810-bile-acids.htm">Bile Acids</a></td><td><p><span></span> <span>colestyramine</span> <span>possibly reduces absorption of</span> <span>bile acids</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int478-cardiac-glycosides.htm">Cardiac Glycosides</a></td><td><p><span></span> <span>colestyramine</span> <span>possibly reduces absorption of</span> <span>cardiac glycosides</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>colestyramine</span> <span>may enhance or reduce anticoagulant effect of</span> <span>coumarins</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int525-diuretics-thiazide-and-related.htm">Diuretics, Thiazide and related</a></td><td><p><span></span> <span>colestyramine</span> <span>reduces absorption of</span> <span>thiazides and related diuretics</span> <span>(give at least 2 hours apart)</span></p></td><td></td></tr><tr><td><a href="bnf_int891-leflunomide.htm">Leflunomide</a></td><td><p><span></span> <span>colestyramine</span> <span>significantly decreases effect of</span> <span>leflunomide</span> <span>(enhanced elimination)—avoid unless drug elimination desired</span></p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with other haematotoxic and hepatotoxic drugs</p></div></td></tr><tr><td><a href="bnf_int74-meloxicam.htm">Meloxicam</a></td><td><p><span></span> <span>colestyramine</span> <span>increases the excretion of</span> <span>meloxicam</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int520-mycophenolate.htm">Mycophenolate</a></td><td><p><span></span> <span>colestyramine</span> <span>reduces absorption of</span> <span>mycophenolate</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int59-paracetamol.htm">Paracetamol</a></td><td><p><span></span> <span>colestyramine</span> <span>reduces absorption of</span> <span>paracetamol</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int223-phenindione.htm">Phenindione</a></td><td class="cAI"><p><span></span> <span>colestyramine</span> <span>may enhance or reduce anticoagulant effect of</span> <span>phenindione</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control  </p></div></td></tr><tr><td><a href="bnf_int864-raloxifene.htm">Raloxifene</a></td><td><p><span></span> <span>colestyramine</span> <span>reduces absorption of</span> <span>raloxifene</span> <span>(manufacturer of <span>raloxifene</span> advises avoid concomitant administration)</span></p></td><td></td></tr><tr><td><a href="bnf_int216-tetracycline.htm">Tetracycline</a></td><td><p><span></span> <span>colestyramine</span> <span>possibly reduces absorption of</span> <span>tetracycline</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int935-thyroid-hormones.htm">Thyroid Hormones</a></td><td><p><span></span> <span>colestyramine</span> <span>reduces absorption of</span> <span>thyroid hormones</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int286-valproate.htm">Valproate</a></td><td><p><span></span> <span>colestyramine</span> <span>possibly reduces absorption of</span> <span>valproate</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int218-vancomycin.htm">Vancomycin</a></td><td><p><span></span> <span>colestyramine</span> <span>antagonises effects of <em>oral</em></span> <span>vancomycin</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Fibrates</strong> belongs to <strong>Lipid-regulating Drugs</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int483-colchicine.htm">Colchicine</a></td><td class="cAI"><p><span>possible increased risk of myopathy when </span><span>fibrates</span> <span>given with</span> <span>colchicine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>fibrates</span> <span>enhance anticoagulant effect of</span> <span>coumarins</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int1061-daptomycin.htm">Daptomycin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>fibrates</span> <span>given with</span> <span>daptomycin</span> <span>(preferably avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int970-ezetimibe.htm">Ezetimibe</a></td><td><p><span>increased risk of cholelithiasis and gallbladder disease when </span><span>fibrates</span> <span>given with</span> <span>ezetimibe</span><span>—discontinue if suspected</span></p></td><td></td></tr><tr><td><a href="bnf_int265-insulin.htm">Insulin</a></td><td><p><span></span> <span>fibrates</span> <span>may improve glucose tolerance and have an additive effect with</span> <span>insulin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int223-phenindione.htm">Phenindione</a></td><td class="cAI"><p><span></span> <span>fibrates</span> <span>enhance anticoagulant effect of</span> <span>phenindione</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control  </p></div></td></tr><tr><td><a href="bnf_int974-rosuvastatin.htm">Rosuvastatin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>fibrates</span> <span>given with</span> <span>rosuvastatin</span> <span>(see Dose under Rosuvastatin, <a title="ROSUVASTATIN (Monograph)" href="PHP1645-rosuvastatin.htm">section 2.12</a>)</span></p></td><td></td></tr><tr><td><a href="bnf_int600-statins.htm">Statins</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>fibrates</span> <span>given with</span> <span>statins</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int268-sulfonylureas.htm">Sulfonylureas</a></td><td><p><span></span> <span>fibrates</span> <span>may improve glucose tolerance and have an additive effect with</span> <span>sulfonylureas</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Bezafibrate</strong> belongs to <strong>Lipid-regulating Drugs</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td><p><span>increased risk of renal impairment when </span><span>bezafibrate</span> <span>given with</span> <span>ciclosporin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td class="cAI"><p><span>possible increased risk of myopathy when </span><span>bezafibrate</span> <span>given with</span> <span>simvastatin</span> <span>(see Dose under Simvastatin, <a title="SIMVASTATIN (Monograph)" href="PHP1647-simvastatin.htm">section 2.12</a>)</span></p></td><td></td></tr></tbody></table><p><strong>Ciprofibrate</strong> belongs to <strong>Lipid-regulating Drugs</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td class="cAI"><p><span>possible increased risk of myopathy when </span><span>ciprofibrate</span> <span>given with</span> <span>simvastatin</span> <span>(see Dose under Simvastatin, <a title="SIMVASTATIN (Monograph)" href="PHP1647-simvastatin.htm">section 2.12</a>)</span></p></td><td></td></tr></tbody></table><p><strong>Fenofibrate</strong> belongs to <strong>Lipid-regulating Drugs</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td><p><span>increased risk of renal impairment when </span><span>fenofibrate</span> <span>given with</span> <span>ciclosporin</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Gemfibrozil</strong> belongs to <strong>Lipid-regulating Drugs</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int601-atorvastatin.htm">Atorvastatin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>gemfibrozil</span> <span>given with</span> <span>atorvastatin</span> <span>(preferably avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int1046-bexarotene.htm">Bexarotene</a></td><td class="cAI"><p><span></span> <span>gemfibrozil</span> <span>increases plasma concentration of</span> <span>bexarotene</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int603-fluvastatin.htm">Fluvastatin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>gemfibrozil</span> <span>given with</span> <span>fluvastatin</span> <span>(preferably avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int845-montelukast.htm">Montelukast</a></td><td><p><span></span> <span>gemfibrozil</span> <span>increases plasma concentration of</span> <span>montelukast</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int920-nateglinide.htm">Nateglinide</a></td><td><p><span></span> <span>gemfibrozil</span> <span>possibly enhances hypoglycaemic effect of</span> <span>nateglinide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int604-pravastatin.htm">Pravastatin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>gemfibrozil</span> <span>given with</span> <span>pravastatin</span> <span>(preferably avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int855-repaglinide.htm">Repaglinide</a></td><td class="cAI"><p><span>increased risk of severe hypoglycaemia when </span><span>gemfibrozil</span> <span>given with</span> <span>repaglinide</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>gemfibrozil</span> <span>given with</span> <span>simvastatin</span> <span>(avoid concomitant use)</span></p></td><td></td></tr></tbody></table><p><strong>Statins</strong> belongs to <strong>Lipid-regulating Drugs</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int483-colchicine.htm">Colchicine</a></td><td class="cAI"><p><span>possible increased risk of myopathy when </span><span>statins</span> <span>given with</span> <span>colchicine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1061-daptomycin.htm">Daptomycin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>statins</span> <span>given with</span> <span>daptomycin</span> <span>(preferably avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int594-fibrates.htm">Fibrates</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>statins</span> <span>given with</span> <span>fibrates</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int163-fusidic-acid.htm">Fusidic Acid</a></td><td class="cAI"><p><span>risk of myopathy and rhabdomyolysis when </span><span>statins</span> <span>given with</span> <span>fusidic acid</span><span>—avoid concomitant use and for 7 days after last <span>fusidic acid</span> dose</span></p></td><td></td></tr><tr><td><a href="bnf_int606-nicotinic-acid.htm">Nicotinic Acid</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>statins</span> <span>given with</span> <span>nicotinic acid</span> <span>(applies to lipid regulating doses of <span>nicotinic acid</span>)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions apply to lipid-regulating doses of nicotinic acid</p></div></td></tr></tbody></table><p><strong>Rosuvastatin</strong> belongs to <strong>Lipid-regulating Drugs</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int110-antacids.htm">Antacids</a></td><td><p><span>absorption of </span><span>rosuvastatin</span> <span>reduced by</span> <span>antacids</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</p></div></td></tr><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td class="cAI"><p><span>possible increased risk of myopathy when </span><span>rosuvastatin</span> <span>given with</span> <span>atazanavir</span><span>—manufacturer of <span>rosuvastatin</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>rosuvastatin</span> <span>given with</span> <span>ciclosporin</span> <span>(avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>rosuvastatin</span> <span>possibly enhances anticoagulant effect of</span> <span>coumarins</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int1091-darunavir.htm">Darunavir</a></td><td class="cAI"><p><span>possible increased risk of myopathy when </span><span>rosuvastatin</span> <span>given with</span> <span>darunavir</span><span>—manufacturer of <span>rosuvastatin</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1176-dronedarone.htm">Dronedarone</a></td><td><p><span>plasma concentration of </span><span>rosuvastatin</span> <span>possibly increased by</span> <span>dronedarone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1177-eltrombopag.htm">Eltrombopag</a></td><td class="cAI"><p><span>plasma concentration of </span><span>rosuvastatin</span> <span>increased by</span> <span>eltrombopag</span> <span>(consider reducing dose of <span>rosuvastatin</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td><p><span>plasma concentration of </span><span>rosuvastatin</span> <span>reduced by</span> <span>erythromycin</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int638-ethinylestradiol.htm">Ethinylestradiol</a></td><td><p><span></span> <span>rosuvastatin</span> <span>increases plasma concentration of</span> <span>ethinylestradiol</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int594-fibrates.htm">Fibrates</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>rosuvastatin</span> <span>given with</span> <span>fibrates</span> <span>(see Dose under Rosuvastatin, <a title="ROSUVASTATIN (Monograph)" href="PHP1645-rosuvastatin.htm">section 2.12</a>)</span></p></td><td></td></tr><tr><td><a href="bnf_int1019-fosamprenavir.htm">Fosamprenavir</a></td><td class="cAI"><p><span>possible increased risk of myopathy when </span><span>rosuvastatin</span> <span>given with</span> <span>fosamprenavir</span><span>—manufacturer of <span>rosuvastatin</span> advises avoid concomitant use</span></p></td><td><div class="cG"><p><strong>Note:</strong> Fosamprenavir is a prodrug of amprenavir</p></div></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td class="cAI"><p><span>possible increased risk of myopathy when </span><span>rosuvastatin</span> <span>given with</span> <span>indinavir</span><span>—manufacturer of <span>rosuvastatin</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int922-lopinavir.htm">Lopinavir</a></td><td class="cAI"><p><span>possible increased risk of myopathy when </span><span>rosuvastatin</span> <span>given with</span> <span>lopinavir</span><span>—manufacturer of <span>rosuvastatin</span> advises avoid concomitant use</span></p></td><td><div class="cG"><p><strong>Note:</strong> In combination with ritonavir as <em>Kaletra</em>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</p></div></td></tr><tr><td><a href="bnf_int674-norgestimate.htm">Norgestimate</a></td><td><p><span></span> <span>rosuvastatin</span> <span>increases plasma concentration of active metabolite of</span> <span>norgestimate</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int675-norgestrel.htm">Norgestrel</a></td><td><p><span></span> <span>rosuvastatin</span> <span>increases plasma concentration of</span> <span>norgestrel</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int223-phenindione.htm">Phenindione</a></td><td class="cAI"><p><span></span> <span>rosuvastatin</span> <span>possibly enhances anticoagulant effect of</span> <span>phenindione</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control  </p></div></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>possible increased risk of myopathy when </span><span>rosuvastatin</span> <span>given with</span> <span>ritonavir</span><span>—manufacturer of <span>rosuvastatin</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>possible increased risk of myopathy when </span><span>rosuvastatin</span> <span>given with</span> <span>saquinavir</span><span>—manufacturer of <span>rosuvastatin</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1055-tipranavir.htm">Tipranavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>rosuvastatin</span> <span>possibly increased by</span> <span>tipranavir</span><span>—manufacturer of <span>rosuvastatin</span> advises avoid concomitant use</span></p></td><td></td></tr></tbody></table><p><strong>Atorvastatin</strong> belongs to <strong>Lipid-regulating Drugs</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int293-antifungals-imidazole.htm">Antifungals, Imidazole</a></td><td><p><span>possible increased risk of myopathy when </span><span>atorvastatin</span> <span>given with</span> <span>imidazoles</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int300-antifungals-triazole.htm">Antifungals, Triazole</a></td><td><p><span>possible increased risk of myopathy when </span><span>atorvastatin</span> <span>given with</span> <span>triazoles</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td class="cAI"><p><span>possible increased risk of myopathy when </span><span>atorvastatin</span> <span>given with</span> <span>atazanavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td class="cAI"><p><span>enhanced effects and increased toxicity of </span><span>atorvastatin</span> <span>when given with</span> <span>boceprevir</span> <span>(reduce dose of <span>atorvastatin</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>atorvastatin</span> <span>given with</span> <span>ciclosporin</span> <span>(see Dose under Atorvastatin, <a title="ATORVASTATIN (Monograph)" href="PHP1633-atorvastatin.htm">section 2.12</a>)</span></p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td class="cAI"><p><span>plasma concentration of </span><span>atorvastatin</span> <span>increased by</span> <span>clarithromycin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1091-darunavir.htm">Darunavir</a></td><td><p><span>possible increased risk of myopathy when </span><span>atorvastatin</span> <span>given with</span> <span>darunavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td><p><span></span> <span>atorvastatin</span> <span>possibly increases plasma concentration of</span> <span>digoxin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int468-diltiazem.htm">Diltiazem</a></td><td><p><span>plasma concentration of </span><span>atorvastatin</span> <span>increased by</span> <span>diltiazem</span><span>—possible increased risk of myopathy</span></p></td><td></td></tr><tr><td><a href="bnf_int1176-dronedarone.htm">Dronedarone</a></td><td><p><span>plasma concentration of </span><span>atorvastatin</span> <span>possibly increased by</span> <span>dronedarone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int874-efavirenz.htm">Efavirenz</a></td><td><p><span>plasma concentration of </span><span>atorvastatin</span> <span>reduced by</span> <span>efavirenz</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td><p><span>possible increased risk of myopathy when </span><span>atorvastatin</span> <span>given with</span> <span>erythromycin</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int638-ethinylestradiol.htm">Ethinylestradiol</a></td><td><p><span></span> <span>atorvastatin</span> <span>increases plasma concentration of</span> <span>ethinylestradiol</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1135-etravirine.htm">Etravirine</a></td><td><p><span>plasma concentration of </span><span>atorvastatin</span> <span>possibly reduced by</span> <span>etravirine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1019-fosamprenavir.htm">Fosamprenavir</a></td><td><p><span>possible increased risk of myopathy when </span><span>atorvastatin</span> <span>given with</span> <span>fosamprenavir</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Fosamprenavir is a prodrug of amprenavir</p></div></td></tr><tr><td><a href="bnf_int599-gemfibrozil.htm">Gemfibrozil</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>atorvastatin</span> <span>given with</span> <span>gemfibrozil</span> <span>(preferably avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int829-grapefruit-juice.htm">Grapefruit Juice</a></td><td><p><span>plasma concentration of </span><span>atorvastatin</span> <span>possibly increased by</span> <span>grapefruit juice</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td><p><span>possible increased risk of myopathy when </span><span>atorvastatin</span> <span>given with</span> <span>indinavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>atorvastatin</span> <span>given with</span> <span>itraconazole</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int922-lopinavir.htm">Lopinavir</a></td><td><p><span>possible increased risk of myopathy when </span><span>atorvastatin</span> <span>given with</span> <span>lopinavir</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> In combination with ritonavir as <em>Kaletra</em>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</p></div></td></tr><tr><td><a href="bnf_int421-midazolam.htm">Midazolam</a></td><td><p><span></span> <span>atorvastatin</span> <span>possibly increases plasma concentration of</span> <span>midazolam</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int673-norethisterone.htm">Norethisterone</a></td><td><p><span></span> <span>atorvastatin</span> <span>increases plasma concentration of</span> <span>norethisterone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1060-posaconazole.htm">Posaconazole</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>atorvastatin</span> <span>given with</span> <span>posaconazole</span> <span>(avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>plasma concentration of </span><span>atorvastatin</span> <span>possibly reduced by</span> <span>rifampicin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td><p><span>possible increased risk of myopathy when </span><span>atorvastatin</span> <span>given with</span> <span>ritonavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td><p><span>possible increased risk of myopathy when </span><span>atorvastatin</span> <span>given with</span> <span>saquinavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td class="cAI"><p><span>avoidance of </span><span>atorvastatin</span> <span>advised by manufacturer of</span> <span>telaprevir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>atorvastatin</span> <span>given with</span> <span>telithromycin</span> <span>(avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int1055-tipranavir.htm">Tipranavir</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>atorvastatin</span> <span>given with</span> <span>tipranavir</span> <span>(see Dose under Atorvastatin, <a title="ATORVASTATIN (Monograph)" href="PHP1633-atorvastatin.htm">section 2.12</a>)</span></p></td><td></td></tr><tr><td><a href="bnf_int222-warfarin.htm">Warfarin</a></td><td><p><span></span> <span>atorvastatin</span> <span>may transiently reduce anticoagulant effect of</span> <span>warfarin</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Fluvastatin</strong> belongs to <strong>Lipid-regulating Drugs</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>fluvastatin</span> <span>given with</span> <span>ciclosporin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>fluvastatin</span> <span>enhances anticoagulant effect of</span> <span>coumarins</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int301-fluconazole.htm">Fluconazole</a></td><td><p><span>plasma concentration of </span><span>fluvastatin</span> <span>increased by</span> <span>fluconazole</span><span>—possible increased risk of myopathy</span></p></td><td><div class="cG"><p><strong>Note:</strong> In general, fluconazole interactions relate to multiple-dose treatment</p></div></td></tr><tr><td><a href="bnf_int599-gemfibrozil.htm">Gemfibrozil</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>fluvastatin</span> <span>given with</span> <span>gemfibrozil</span> <span>(preferably avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int270-glibenclamide.htm">Glibenclamide</a></td><td><p><span></span> <span>fluvastatin</span> <span>possibly increases plasma concentration of</span> <span>glibenclamide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>combination of </span><span>fluvastatin</span> <span>with</span> <span>phenytoin</span> <span>may increase plasma concentration of either drug (or both)</span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>metabolism of </span><span>fluvastatin</span> <span>accelerated by</span> <span>rifampicin</span> <span>(reduced effect)</span></p></td><td></td></tr></tbody></table><p><strong>Pravastatin</strong> belongs to <strong>Lipid-regulating Drugs</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td><p><span>possible increased risk of myopathy when </span><span>pravastatin</span> <span>given with</span> <span>atazanavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td><p><span>plasma concentration of </span><span>pravastatin</span> <span>increased by</span> <span>boceprevir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>pravastatin</span> <span>given with</span> <span>ciclosporin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td><p><span>plasma concentration of </span><span>pravastatin</span> <span>increased by</span> <span>clarithromycin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1091-darunavir.htm">Darunavir</a></td><td><p><span>plasma concentration of </span><span>pravastatin</span> <span>possibly increased by</span> <span>darunavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int874-efavirenz.htm">Efavirenz</a></td><td><p><span>plasma concentration of </span><span>pravastatin</span> <span>reduced by</span> <span>efavirenz</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td><p><span>plasma concentration of </span><span>pravastatin</span> <span>increased by</span> <span>erythromycin</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int599-gemfibrozil.htm">Gemfibrozil</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>pravastatin</span> <span>given with</span> <span>gemfibrozil</span> <span>(preferably avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td><p><span>possible increased risk of myopathy when </span><span>pravastatin</span> <span>given with</span> <span>telithromycin</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Simvastatin</strong> belongs to <strong>Lipid-regulating Drugs</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1124-alitretinoin.htm">Alitretinoin</a></td><td><p><span>plasma concentration of </span><span>simvastatin</span> <span>reduced by</span> <span>alitretinoin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int118-amiodarone.htm">Amiodarone</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>simvastatin</span> <span>given with</span> <span>amiodarone</span> <span>(see Dose under Simvastatin, <a title="SIMVASTATIN (Monograph)" href="PHP1647-simvastatin.htm">section 2.12</a>)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div></td></tr><tr><td><a href="bnf_int470-amlodipine.htm">Amlodipine</a></td><td class="cAI"><p><span>possible increased risk of myopathy when </span><span>simvastatin</span> <span>given with</span> <span>amlodipine</span> <span>(see Dose under Simvastatin, <a title="SIMVASTATIN (Monograph)" href="PHP1647-simvastatin.htm">section 2.12</a>)</span></p></td><td></td></tr><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>simvastatin</span> <span>given with</span> <span>atazanavir</span> <span>(avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int596-bezafibrate.htm">Bezafibrate</a></td><td class="cAI"><p><span>possible increased risk of myopathy when </span><span>simvastatin</span> <span>given with</span> <span>bezafibrate</span> <span>(see Dose under Simvastatin, <a title="SIMVASTATIN (Monograph)" href="PHP1647-simvastatin.htm">section 2.12</a>)</span></p></td><td></td></tr><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td class="cAI"><p><span>manufacturers advise avoid concomitant use of </span><span>simvastatin</span> <span>with</span> <span>boceprevir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int943-bosentan.htm">Bosentan</a></td><td><p><span>plasma concentration of </span><span>simvastatin</span> <span>reduced by</span> <span>bosentan</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span>plasma concentration of </span><span>simvastatin</span> <span>reduced by</span> <span>carbamazepine</span><span>—consider increasing dose of <span>simvastatin</span></span></p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>simvastatin</span> <span>given with</span> <span>ciclosporin</span> <span>(avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int597-ciprofibrate.htm">Ciprofibrate</a></td><td class="cAI"><p><span>possible increased risk of myopathy when </span><span>simvastatin</span> <span>given with</span> <span>ciprofibrate</span> <span>(see Dose under Simvastatin, <a title="SIMVASTATIN (Monograph)" href="PHP1647-simvastatin.htm">section 2.12</a>)</span></p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>simvastatin</span> <span>given with</span> <span>clarithromycin</span> <span>(avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td><p><span></span> <span>simvastatin</span> <span>enhances anticoagulant effect of</span> <span>coumarins</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int579-danazol.htm">Danazol</a></td><td class="cAI"><p><span>possible increased risk of myopathy when </span><span>simvastatin</span> <span>given with</span> <span>danazol</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1077-dasatinib.htm">Dasatinib</a></td><td><p><span>plasma concentration of </span><span>simvastatin</span> <span>possibly increased by</span> <span>dasatinib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int468-diltiazem.htm">Diltiazem</a></td><td><p><span>possible increased risk of myopathy when </span><span>simvastatin</span> <span>given with</span> <span>diltiazem</span> <span>(see Dose under Simvastatin, <a title="SIMVASTATIN (Monograph)" href="PHP1647-simvastatin.htm">section 2.12</a>)</span></p></td><td></td></tr><tr><td><a href="bnf_int1176-dronedarone.htm">Dronedarone</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>simvastatin</span> <span>given with</span> <span>dronedarone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int874-efavirenz.htm">Efavirenz</a></td><td><p><span>plasma concentration of </span><span>simvastatin</span> <span>reduced by</span> <span>efavirenz</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>simvastatin</span> <span>given with</span> <span>erythromycin</span> <span>(avoid concomitant use)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int1153-eslicarbazepine.htm">Eslicarbazepine</a></td><td><p><span>plasma concentration of </span><span>simvastatin</span> <span>reduced by</span> <span>eslicarbazepine</span><span>—consider increasing dose of <span>simvastatin</span></span></p></td><td></td></tr><tr><td><a href="bnf_int301-fluconazole.htm">Fluconazole</a></td><td class="cAI"><p><span>possible increased risk of myopathy when </span><span>simvastatin</span> <span>given with</span> <span>fluconazole</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> In general, fluconazole interactions relate to multiple-dose treatment</p></div></td></tr><tr><td><a href="bnf_int1019-fosamprenavir.htm">Fosamprenavir</a></td><td class="cAI"><p><span>possible increased risk of myopathy when </span><span>simvastatin</span> <span>given with</span> <span>fosamprenavir</span><span>—avoid concomitant use</span></p></td><td><div class="cG"><p><strong>Note:</strong> Fosamprenavir is a prodrug of amprenavir</p></div></td></tr><tr><td><a href="bnf_int599-gemfibrozil.htm">Gemfibrozil</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>simvastatin</span> <span>given with</span> <span>gemfibrozil</span> <span>(avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int829-grapefruit-juice.htm">Grapefruit Juice</a></td><td class="cAI"><p><span>plasma concentration of </span><span>simvastatin</span> <span>increased by</span> <span>grapefruit juice</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int933-imatinib.htm">Imatinib</a></td><td><p><span>plasma concentration of </span><span>simvastatin</span> <span>increased by</span> <span>imatinib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>simvastatin</span> <span>given with</span> <span>indinavir</span> <span>(avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>simvastatin</span> <span>given with</span> <span>itraconazole</span> <span>(avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>simvastatin</span> <span>given with</span> <span>ketoconazole</span> <span>(avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int922-lopinavir.htm">Lopinavir</a></td><td class="cAI"><p><span>possible increased risk of myopathy when </span><span>simvastatin</span> <span>given with</span> <span>lopinavir</span><span>—avoid concomitant use</span></p></td><td><div class="cG"><p><strong>Note:</strong> In combination with ritonavir as <em>Kaletra</em>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</p></div></td></tr><tr><td><a href="bnf_int299-miconazole.htm">Miconazole</a></td><td class="cAI"><p><span>possible increased risk of myopathy when </span><span>simvastatin</span> <span>given with</span> <span>miconazole</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1060-posaconazole.htm">Posaconazole</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>simvastatin</span> <span>given with</span> <span>posaconazole</span> <span>(avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int1147-ranolazine.htm">Ranolazine</a></td><td class="cAI"><p><span>plasma concentration of </span><span>simvastatin</span> <span>increased by</span> <span>ranolazine</span> <span>(see Dose under Simvastatin, <a title="SIMVASTATIN (Monograph)" href="PHP1647-simvastatin.htm">section 2.12</a>)</span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>plasma concentration of </span><span>simvastatin</span> <span>possibly reduced by</span> <span>rifampicin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>simvastatin</span> <span>given with</span> <span>ritonavir</span> <span>(avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>simvastatin</span> <span>given with</span> <span>saquinavir</span> <span>(avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td><p><span>plasma concentration of </span><span>simvastatin</span> <span>reduced by</span> <span>St John's wort</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td class="cAI"><p><span>manufacturers advise avoid concomitant use of </span><span>simvastatin</span> <span>with</span> <span>telaprevir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>simvastatin</span> <span>given with</span> <span>telithromycin</span> <span>(avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int1203-ticagrelor.htm">Ticagrelor</a></td><td class="cAI"><p><span>plasma concentration of </span><span>simvastatin</span> <span>increased by</span> <span>ticagrelor</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int1055-tipranavir.htm">Tipranavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>simvastatin</span> <span>possibly increased by</span> <span>tipranavir</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int467-verapamil.htm">Verapamil</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>simvastatin</span> <span>given with</span> <span>verapamil</span> <span>(see Dose under Simvastatin, <a title="SIMVASTATIN (Monograph)" href="PHP1647-simvastatin.htm">section 2.12</a>)</span></p></td><td></td></tr><tr><td><a href="bnf_int948-voriconazole.htm">Voriconazole</a></td><td><p><span>possible increased risk of myopathy when </span><span>simvastatin</span> <span>given with</span> <span>voriconazole</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Nicotinic Acid</strong> belongs to <strong>Lipid-regulating Drugs</strong> and has the following interaction information:</p><div class="cG"><p><strong>Note:</strong> Interactions apply to lipid-regulating doses of nicotinic acid</p></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int600-statins.htm">Statins</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>nicotinic acid</span> <span>given with</span> <span>statins</span> <span>(applies to lipid regulating doses of <span>nicotinic acid</span>)</span></p></td><td></td></tr></tbody></table></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="bnf_int970-ezetimibe.htm" title="Ezetimibe">Ezetimibe</a></li><li id="_bnf_int591-bile-acid-sequestrants"><a href="bnf_int591-bile-acid-sequestrants.htm" title="Bile Acid Sequestrants ">Bile Acid Sequestrants </a></li><li id="_bnf_int594-fibrates"><a href="bnf_int594-fibrates.htm" title="Fibrates">Fibrates</a></li><li id="_bnf_int600-statins"><a href="bnf_int600-statins.htm" title="Statins">Statins</a></li><li><a href="bnf_int606-nicotinic-acid.htm" title="Nicotinic Acid">Nicotinic Acid</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="bnf_int1032-levamisole.htm">Previous: Levamisole</a> | <a class="top" href="bnf_int590-lipid-regulating-drugs.htm#">Top</a> | <a accesskey="]" href="bnf_int970-ezetimibe.htm">Next: Ezetimibe</a> ►</div></div></div></div><div id="pF"><div id="p2"><div id="pL"><div class="p4"><h2>Keep in touch</h2><ul><li><a href="http://www.pharmpress.com/?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Pharmaceutical Press</a></li><li><a href="http://www.rpharms.com/">Royal Pharmaceutical Society</a></li><li><a href="http://www.pharmpress.com/mc-alerts.asp?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Sign up for our eNewsletter</a></li><li><a href="http://twitter.com/#!/PharmPress/" class="p5"><img src="../../images/twitter.png" alt="Twitter logo" />Follow us on Twitter
              </a></li><li><a href="http://www.facebook.com/pages/Pharmaceutical-Press/296104187066918" class="p5"><img src="../../images/facebook.png" alt="Facebook logo" />Find us on Facebook
              </a></li></ul></div><div class="p4"><h2>Help and Support</h2><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a></li><li><a href="http://www.medicinescomplete.com/about/contact.htm">Contact Us</a></li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a></li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a></li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div><div class="p4"><h2>Provided for</h2><div id="cL"><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2013.  All rights reserved.</a></p><p><a href="http://www.medicinescomplete.com/mc/copyright.htm">MedicinesComplete © The Pharmaceutical Press 2013</a></p></div></div></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>